Status:

RECRUITING

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.

Lead Sponsor:

Genentech, Inc.

Conditions:

Chronic Lymphocytic Leukemia

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD ...

Eligibility Criteria

Inclusion

  • Diagnosed with CLL and currently receiving a stable dose of cBTKi (i.e., ibrutinib, acalabrutinib, or zanubrutinib) for at least 6 months for 1L treatment with a response of at least a PR per iwCLL criteria
  • Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to (\</=) 2
  • Adequate renal and liver function

Exclusion

  • Prior B-cell lymphoma (Bcl-2) inhibitor therapy
  • Anti-cluster of differentiation 20 (CD20) therapy within the month prior to screening
  • Progressive or stable disease on cBTKi
  • Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (Richter's transformation or pro-lymphocytic leukemia)
  • History of cardiomyopathy
  • Hypersensitivity to venetoclax or to any of the excipients (e.g., trehalose)
  • Clinically significant cardiovascular disease
  • Active bleeding or history of bleeding diathesis
  • Pregnant women and nursing mothers
  • Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia

Key Trial Info

Start Date :

August 9 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 8 2028

Estimated Enrollment :

110 Patients enrolled

Trial Details

Trial ID

NCT06524375

Start Date

August 9 2024

End Date

February 8 2028

Last Update

October 14 2025

Active Locations (21)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (21 locations)

1

Highlands Oncology Group

Springdale, Arkansas, United States, 72762

2

Rocky Mountain Cancer Centers (Aurora) - USOR

Aurora, Colorado, United States, 80012-5405

3

Cancer Specialists of North Florida

Jacksonville, Florida, United States, 32256-6932

4

University Cancer & Blood Center, LLC

Athens, Georgia, United States, 30607